Literature DB >> 18832948

Penile rehabilitation following radical prostatectomy.

John P Mulhall1.   

Abstract

PURPOSE OF REVIEW: Erectile dysfunction is common after radical prostatectomy. Erectile dysfunction has a negative impact on health-related quality of life. Penile rehabilitation is defined as the use of any drug or device at or after radical prostatectomy to maximize erectile function recovery. This is an up-to-date review of the current state of science supporting penile rehabilitation after radical prostatectomy. RECENT
FINDINGS: The purpose of penile rehabilitation is to prevent corpus cavernosal smooth muscle structural alterations to not only maximize the chances of a man to recover functional erections but also return him to his preoperative erectile function level. Current animal and human data support the use of PDE5 inhibitor and the generation of early erections after radical prostatectomy as a strategy to improve erectile function recovery. The magnitude of this improvement is currently unclear.
SUMMARY: The results from animal and human studies imply that the use of PDE5 inhibitor and the generation of erections early after radical prostatectomy are of some benefit to erectile function recovery. Although the definitive protocol for rehabilitation is not defined, future work is aimed at determining this.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832948     DOI: 10.1097/MOU.0b013e3283136462

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  28 in total

1.  Should penile rehabilitation become the norm following radical prostatectomy?

Authors:  Tariq Al Shaiji; Mb Chb; Gerald Brock
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

2.  Dr. Al Shaiji and Dr. Brock's rebuttal.

Authors: 
Journal:  Can Urol Assoc J       Date:  2009-02       Impact factor: 1.862

3.  Postprostatectomy erectile dysfunction: the role of penile rehabilitation.

Authors:  Brian P Defade; Culley C Carson; Michael J Kennelly
Journal:  Rev Urol       Date:  2011

4.  Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats.

Authors:  Johanna L Hannan; Omer Kutlu; Bernard L Stopak; Xiaopu Liu; Fabio Castiglione; Petter Hedlund; Arthur L Burnett; Trinity J Bivalacqua
Journal:  J Sex Med       Date:  2014-03-18       Impact factor: 3.802

5.  Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury.

Authors:  Johanna L Hannan; Maarten Albersen; Omer Kutlu; Christian Gratzke; Christian G Stief; Arthur L Burnett; Jeffrey J Lysiak; Petter Hedlund; Trinity J Bivalacqua
Journal:  J Urol       Date:  2012-09-25       Impact factor: 7.450

Review 6.  Therapeutic strategies for patients with micropenis or penile dysmorphic disorder.

Authors:  Oliver Kayes; Majid Shabbir; David Ralph; Suks Minhas
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

7.  Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

Authors:  Monica G Ferrini; Joanne Moon; Steve Rivera; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

Review 8.  Erection rehabilitation following prostatectomy--current strategies and future directions.

Authors:  Nikolai A Sopko; Arthur L Burnett
Journal:  Nat Rev Urol       Date:  2016-03-15       Impact factor: 14.432

9.  Neurotrophic effects of brain-derived neurotrophic factor and vascular endothelial growth factor in major pelvic ganglia of young and aged rats.

Authors:  Guiting Lin; Alan W Shindel; Thomas M Fandel; Anthony J Bella; Ching-Shwun Lin; Tom F Lue
Journal:  BJU Int       Date:  2009-06-02       Impact factor: 5.588

Review 10.  The role and structure of a postradical prostatectomy penile rehabilitation program.

Authors:  John P Mulhall
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.